UY32546A - Composiciones y metodos para tratar cancer - Google Patents
Composiciones y metodos para tratar cancerInfo
- Publication number
- UY32546A UY32546A UY0001032546A UY32546A UY32546A UY 32546 A UY32546 A UY 32546A UY 0001032546 A UY0001032546 A UY 0001032546A UY 32546 A UY32546 A UY 32546A UY 32546 A UY32546 A UY 32546A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- compositions
- treat cancer
- decitabine
- inactivation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 abstract 2
- 229960003603 decitabine Drugs 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000009615 deamination Effects 0.000 abstract 1
- 238000006481 deamination reaction Methods 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16711909P | 2009-04-06 | 2009-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY32546A true UY32546A (es) | 2010-10-29 |
Family
ID=42357480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001032546A UY32546A (es) | 2009-04-06 | 2010-04-06 | Composiciones y metodos para tratar cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8329666B2 (https=) |
| EP (1) | EP2416780B1 (https=) |
| JP (1) | JP5730854B2 (https=) |
| AR (1) | AR076263A1 (https=) |
| AU (1) | AU2010234641B2 (https=) |
| CA (1) | CA2757744C (https=) |
| ES (1) | ES2628580T3 (https=) |
| JO (1) | JO3262B1 (https=) |
| TW (1) | TWI503121B (https=) |
| UY (1) | UY32546A (https=) |
| WO (1) | WO2010118010A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2870937B2 (ja) | 1990-02-26 | 1999-03-17 | 凸版印刷株式会社 | 金属蒸着フィルムの製造方法 |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
| JP5687687B2 (ja) * | 2009-04-06 | 2015-03-18 | 大塚製薬株式会社 | 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体 |
| AU2010234562B2 (en) * | 2009-04-06 | 2016-05-12 | Taiho Pharmaceutical Co., Ltd. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
| DK3383406T3 (da) | 2015-12-03 | 2022-01-10 | Epidestiny Inc | Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf |
| KR20190097240A (ko) | 2016-12-28 | 2019-08-20 | 트랜스진 에스.에이. | 종양용해성 바이러스 및 치료 분자 |
| US11224610B2 (en) | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| JP7419391B2 (ja) | 2019-03-29 | 2024-01-22 | ノボキュア ゲーエムベーハー | ＰＴＧＥＲ３阻害剤によりＴＴＦｉｅｌｄｓ－耐性がん細胞におけるＴＴＦｉｅｌｄｓに対する感受性を回復させるための方法 |
| KR20240108406A (ko) | 2021-10-19 | 2024-07-09 | 아키라바이오, 인크. | 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017606A (en) * | 1973-10-04 | 1977-04-12 | The Upjohn Company | Organic compounds and process |
| US4275057A (en) * | 1980-01-28 | 1981-06-23 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Seven-membered ring compounds as inhibitors of cytidine deaminase |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| EP0160079B1 (en) | 1983-10-26 | 1990-01-31 | GREER, Sheldon B. | Method and materials for sensitizing neoplastic tissue to radiation |
| ATE92499T1 (de) * | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
| US5223608A (en) * | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US4965374A (en) * | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| FR2682112B1 (fr) * | 1991-10-08 | 1993-12-10 | Commissariat A Energie Atomique | Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection. |
| US5606048A (en) * | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5426183A (en) * | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5594124A (en) * | 1992-06-22 | 1997-01-14 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof |
| US5821357A (en) * | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
| US5371210A (en) * | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| WO1994019362A1 (en) * | 1993-02-23 | 1994-09-01 | City Of Hope | 4-ethoxy 5-fluoro 2'deoxyuridine |
| WO1994026761A1 (en) | 1993-05-14 | 1994-11-24 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
| US5637688A (en) * | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
| US5521294A (en) * | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
| US6001994A (en) * | 1995-12-13 | 1999-12-14 | Eli Lilly And Company | Process for making gemcitabine hydrochloride |
| US5760208A (en) * | 1996-08-14 | 1998-06-02 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Process to prepare pyrimidine nucleosides |
| ATE339960T1 (de) | 1999-03-01 | 2006-10-15 | Halogenetics Inc | Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen |
| US6933287B1 (en) * | 1999-03-01 | 2005-08-23 | Sheldon B. Greer | Dramatic simplification of a method to treat neoplastic disease by radiation |
| US6462191B1 (en) * | 2000-07-13 | 2002-10-08 | Air Products And Chemicals, Inc. | Synthesis of 2-deoxy-2-fluoro-arabinose derivatives |
| DE60144573D1 (de) | 2000-11-29 | 2011-06-16 | Mitsui Chemicals Inc | Verfahren und Zwischenprodukte bei der Synthese von L-Thymidin |
| DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| EP1387850A2 (en) | 2001-05-18 | 2004-02-11 | Rakesh Kumar | Antiviral nucleosides |
| AU2003278904A1 (en) | 2002-09-24 | 2004-04-19 | Kornis Pharmaceuticals, Incorporated | 1, 3, 5-triazines for treatment of viral diseases |
| US8158770B2 (en) * | 2004-05-06 | 2012-04-17 | University Of Rochester | Content dependent inhibitors of cytidine deaminases and uses thereof |
| WO2006015346A1 (en) | 2004-07-30 | 2006-02-09 | Pharmaessentia Corp. | STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES |
| WO2006063105A1 (en) | 2004-12-08 | 2006-06-15 | Sicor Inc. | Difluoronucleosides and process for preparation thereof |
| WO2008085611A2 (en) | 2006-11-27 | 2008-07-17 | University Of Miami | Designer theraphy of pancreatic tumors |
| WO2009021551A1 (en) | 2007-08-13 | 2009-02-19 | Universite De La Mediterranee | A method for assessing the risk of toxicity in a chemotherapy |
| JO2778B1 (en) * | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| WO2010047698A1 (en) | 2008-10-22 | 2010-04-29 | University Of Alabama At Birmingham | Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases |
| AU2010234562B2 (en) * | 2009-04-06 | 2016-05-12 | Taiho Pharmaceutical Co., Ltd. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
| JP5687687B2 (ja) * | 2009-04-06 | 2015-03-18 | 大塚製薬株式会社 | 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体 |
-
2010
- 2010-04-06 UY UY0001032546A patent/UY32546A/es active IP Right Grant
- 2010-04-06 JO JOP/2010/0108A patent/JO3262B1/ar active
- 2010-04-06 EP EP10713755.6A patent/EP2416780B1/en active Active
- 2010-04-06 JP JP2012504773A patent/JP5730854B2/ja active Active
- 2010-04-06 AR ARP100101143A patent/AR076263A1/es not_active Application Discontinuation
- 2010-04-06 US US12/755,122 patent/US8329666B2/en active Active
- 2010-04-06 CA CA2757744A patent/CA2757744C/en active Active
- 2010-04-06 TW TW099110582A patent/TWI503121B/zh active
- 2010-04-06 AU AU2010234641A patent/AU2010234641B2/en active Active
- 2010-04-06 WO PCT/US2010/030078 patent/WO2010118010A1/en not_active Ceased
- 2010-04-06 ES ES10713755.6T patent/ES2628580T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012522841A (ja) | 2012-09-27 |
| TW201102072A (en) | 2011-01-16 |
| US8329666B2 (en) | 2012-12-11 |
| AU2010234641A1 (en) | 2011-11-10 |
| US20100279967A1 (en) | 2010-11-04 |
| CA2757744A1 (en) | 2010-10-14 |
| WO2010118010A1 (en) | 2010-10-14 |
| JP5730854B2 (ja) | 2015-06-10 |
| TWI503121B (zh) | 2015-10-11 |
| EP2416780A1 (en) | 2012-02-15 |
| ES2628580T3 (es) | 2017-08-03 |
| JO3262B1 (ar) | 2018-09-16 |
| CA2757744C (en) | 2018-02-13 |
| EP2416780B1 (en) | 2017-03-08 |
| AR076263A1 (es) | 2011-06-01 |
| AU2010234641B2 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY32546A (es) | Composiciones y metodos para tratar cancer | |
| NI201200090A (es) | Composiciones para tratar náusea y vómito centralmente mediados | |
| MY191825A (en) | Therapeutic compounds and compositions | |
| CO6321188A2 (es) | Tratamiento de cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de parp | |
| ECSP10010697A (es) | Inhibidores de dpp-iv para uso en el tratamiento de nafld | |
| MX392752B (es) | Terapia de combinacion para tratar cancer. | |
| MX342274B (es) | Actividades de la piruvato quinasa m2 (pkm2). | |
| BR112015011830A2 (pt) | compostos e seus métodos de utilização | |
| NI201200030A (es) | Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas. | |
| MX351028B (es) | Determinadadas entidades, composiciones y metodos quimicos. | |
| GB0920703D0 (en) | Compositions containing satiogens and methods of use | |
| CO6430487A2 (es) | Anticuerpos anti-her | |
| MY160041A (en) | Compositions and methods for treating parasitic infections | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| DK2252322T3 (da) | Vaccinesammensætninger | |
| AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
| CR20120508A (es) | PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES | |
| PH12014501639B1 (en) | Pharmaceutical compositions and methods | |
| WO2009114703A3 (en) | Combination therapy for the treatment of cancer | |
| IN2014DN08385A (https=) | ||
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| CR20110022A (es) | Nuevas posibilidades de lucha contra la giardiasis | |
| GT201300148A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek | |
| NI201300052A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| CO6721062A2 (es) | Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 110 | Patent granted |
Effective date: 20210907 |